7C01

Molecular basis for a potent human neutralizing antibody targeting SARS-CoV-2 RBD

7C01 の概要

• エントリーDOI: 10.2210/pdb7c01/pdb
• 分子名称: Spike protein S1, CB6 heavy chain, CB6 light chain, ... (4 entities in total)
• 機能のキーワード: sars-cov-2, rbd, neutralizing antibodies, molecular basis, viral protein
• 由来する生物種: Severe acute respiratory syndrome coronavirus 2 (2019-nCoV); 詳細
• タンパク質・核酸の鎖数: 6
• 化学式量合計: 149683.28

構造登録者

Shi, R.,Qi, J.,Wang, Q.,Gao, F.G.,Yan, J. (登録日: 2020-04-29, 公開日: 2020-05-27, 最終更新日: 2024-11-20)

主引用文献

Shi, R.,Shan, C.,Duan, X.,Chen, Z.,Liu, P.,Song, J.,Song, T.,Bi, X.,Han, C.,Wu, L.,Gao, G.,Hu, X.,Zhang, Y.,Tong, Z.,Huang, W.,Liu, W.J.,Wu, G.,Zhang, B.,Wang, L.,Qi, J.,Feng, H.,Wang, F.S.,Wang, Q.,Gao, G.F.,Yuan, Z.,Yan, J.
A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2.
Nature, 584:120-124, 2020

PubMed Abstract: An outbreak of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread globally. Countermeasures are needed to treat and prevent further dissemination of the virus. Here we report the isolation of two specific human monoclonal antibodies (termed CA1 and CB6) from a patient convalescing from COVID-19. CA1 and CB6 demonstrated potent SARS-CoV-2-specific neutralization activity in vitro. In addition, CB6 inhibited infection with SARS-CoV-2 in rhesus monkeys in both prophylactic and treatment settings. We also performed structural studies, which revealed that CB6 recognizes an epitope that overlaps with angiotensin-converting enzyme 2 (ACE2)-binding sites in the SARS-CoV-2 receptor-binding domain, and thereby interferes with virus-receptor interactions by both steric hindrance and direct competition for interface residues. Our results suggest that CB6 deserves further study as a candidate for translation to the clinic.

PubMed: 32454512
DOI: 10.1038/s41586-020-2381-y

実験手法

X-RAY DIFFRACTION (2.88 Å)